RR. The authority vested in the Secretary or that may become vested in the Secretary, and not otherwise delegated, limited, or reserved, to conduct studies and demonstration projects, as directed by Congress, that relate to the programs established by Title XI of the Social Security Act (Act), insofar as they relate to the mission of the Health Care Financing Administration (HCFA), and Titles XVIII, XIX, and XXI. This delegation encompasses the authority to approve related program activities required by the studies and demonstration projects if such authority is or becomes vested in the Secretary and is not otherwise delegated, limited, or reserved. These activities include, but are not limited to, direct performance, entering into contracts or cooperative agreements, making grants, approving payments for contracts, cooperative agreements, and grants and approving authorized waivers of compliance with certain requirements of titles XI, XVIII, and XIX and XXI of the Act when such actions are for the purpose of conducting studies and demonstration projects.

This delegation shall be exercised under the Department's existing delegation of authority and policy on regulations. In addition, I hereby ratify and affirm any actions taken by the Administrator or other HCFA officials which, in effect, involved the exercise of this authority prior to the effective date of this delegation. This delegation is effective immediately.

Dated: December 2, 1997.

Donna E. Shalala,

Secretary.

[FR Doc. 97-32747 Filed 12-15-97; 8:45 am]

BILLING CODE 4120-03-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

Name of SEP: Cancer Education Program, Telephone Conference Call.

Date: December 18, 1997.

Time: 3:30 p.m. to Adjournment. Place: National Cancer Institute, Executive Plaza North, Room 611A, 6130 Executive Boulevard, Bethesda, MD 20892.

Contact Person: Mary Bell, Ph.D., Scientific Review Administrator, National Cancer

Institute, NIH, Executive Plaza North, Room 611A, 6130 Executive Boulevard, Bethesda, MD 20892, Telephone: 301/496-7978.

Purpose/Agenda: To review, discuss and evaluate grant applications.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Grant applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research: 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower, 93.399, Cancer Control.)

Dated: December 10, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH. [FR Doc. 97-32745 Filed 12-15-97; 8:45 am] BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND **HUMAN RESOURCES**

National Institutes of Health

Electric and Magnetic Fields Research and Public Information; Dissemination (EMFRAPID) Program; Environmental **Toxicology Program, Office of Special Programs: National Institute of Environmental Health Sciences**, **National Institutes of Health**

NOTICE: Second EMF Science Review Symposium—EMFRAPID Program.

Background

The National Institute of Environmental Health Sciences (NIEHS) and the Department of Energy (DOE) are coordinating the implementation of the Electric and Magnetic Fields (EMF) Research and Public Information Dissemination (RAPID) Program. EMFRAPID was established by the 1992 Energy Policy Act (Section 2118 for Public Law 102-486) which was signed in October 1992. This five-year effort is designed to determine the potential effect from exposure to 60 Hz electric and magnetic fields on biological systems, especially those produced by the generation, transmission and use of electric energy. DOE is responsible for characterizing field exposures and for mitigating exposures which may be hazardous. The NIEHS is responsible for the development and implementation of a research program on the possible human health effects of electric and magnetic fields (EMF). The RAPID Program requires the NIEHS to report on the extent to which exposure to electric and magnetic fields adversely affects human health.

The NIEHS has three groups that assist in managing and directing the science portion of RAPID and who will provide guidance on reporting on the health effects of electric and magnetic fields. The first, known as the Interagency Agency Committee on Electric and Magnetic Fields (IAC) is composed of representatives from 10 federal agencies with responsibilities related to electric and magnetic fields (DOE, NIEHS, the Environmental Protection Agency (EPA), the Department of Defense (DOD), the Occupational Safety and Health Administration (OŠHA), the National Institute of Standards and Technology (NIST), the Department of Transportation (DOT), the Rural Electrification Administration (REA), the Department of the Interior (DOI), and the Federal Energy Regulatory Commission (FERC)). The IAC, established by the President of the United States, must also prepare a final report for Congress.

The second is the National Electric and Magnetic Field Advisory Committee (NEMFAC). NEMFAC consists of representatives from public interest groups, organized labor, state governments, academia, and industry. This groups advises DOE and NIEHS on the design and implementation of the program. NEMFAC also provides recommendations to the IAC.

Finally, the NIEHSA has an internal EMF Steering Committee (SC) consisting of senior scientists with broad programmatic responsibilities and a broad scientific perspective. The SC manages all aspects of the EMFRAPID Research Program at the NIEHS.

NIEHS Report on Human Health Effects of EMF

The report development process combines a critical evaluation of the scientific literature with an assessment of the strength of the evidence for human health effects resulting from EMF exposures. To accomplish the initial part of this process, the NIEHS is convening a series of open, public symposia on science related to EMF exposures and their biological effects for these study areas: theoretical/in vitro research findings, epidemiological results, and in vivo/clinical laboratory findings. The symposia (March 1997, January 1998, and April 1998) provide

a forum for the discussion and evaluation of the research findings in the selected area. At each symposia the participants consider the quality and reproducibility of the research findings for evaluating the degree to which scientific evidence can support a causal linkage between EMF and biological/ health effects. Written reports summarizing the deliberations of breakout group discussion sessions are publicly available for the first symposium (send name and address to f:919-541-0144 or from EMFRAPID Progrm/LCBRA, NIEHS, PO Box 12233, MD EC-16, Research Triangle Park, NC 27709). The participants for each symposium include scientists studying EMF effects in the science area being reviewed, experts on measuring and producing EMF exposures, risk assessment experts, and recognized scientists in the area being evaluated who may have little EMF experience but can contribute to a broader understanding of the research findings.

Following the symposia a working group meeting is planned for June 1998. The working group will use information from the symposia's discussions as well as perform on overall critical evaluation of the literature and produce a report. This document will draw conclusions on the strength and robustness of the data and its implications for human health effects and disease etiology.

Per the request from Congress, the NIEHS will use the final report of the working group, information obtained from the science review symposia and other relevant information to prepare a report to Congress on the potential for human health effects from exposure to EMF that result from the production and distribution of electricity. This report will be made publicly available at the time it is sent to Congress. Detailed information about the EMFRAPID Program is available at the time it is sent to Congress. Detailed information about the EMFRAPID Program is available on the world wide web at www.niehs.nih.gov/emfrapid/ home.htm.

Science Review Symposium on Epidemiology: Open to the Public

In its series of science review symposia, the second EMF Science Review Symposium is scheduled for January 12–14, 1998 at the Camberley Gunter Hotel, San Antonio, Texas. This meeting includes plenary overview talks on exposure assessment, methodological issues and problems in epidemiological studies as well as substantive talks on disease endpoints. Breakout group sessions are planned for in-depth discussions of the research findings

from epidemiological studies as well as methodological and exposure assessment issues. This meeting is open to the public and the registration fee is \$85; for registration information contact t:919-541-7534 or f:919-541-0144.

Science Review Symposium on Clinical and In vivo Research Studies

Planning is underway for the third EMF Science Review Symposium, April 6–9, 1998 at the Hyatt Regency at Civic Plaza, Phoenix, Arizona. To receive additional information about this meeting, send your name and address to f:919–541–0144 or EMFRAPID Program/LCBRA, NIEHS, PO Box 12233, MD EC–16, Research Triange Park, NC 27709.

Dated: December 2, 1997.

Samuel H. Wilson,

Deputy Director, National Institute of Environmental Health Sciences.
[FR Doc. 97–32742 Filed 12–15–97; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Meeting: AIDS Research Advisory Committee, NIAID

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the AIDS Research Advisory Committee, National Institute of Allergy and Infectious Diseases, on January 28, 1998 in Conference Room 1A1 in the Solar Building located at 6003 Executive Blvd, Rockville, Maryland.

The entire meeting will be open to the public from 8:30 a.m. until adjournment. The AIDS Research Advisory Committee (ARAC) advises and makes recommendations to the Director, National Institute of Allergy and Infectious Diseases, on all aspects of research on HIV and AIDS related to the mission of the Division of AIDS (DAIDS).

The Committee will provide advice on scientific priorities, policy, and program balance at the Division level. The Committee will review the progress and productivity of ongoing efforts, and identify critical gaps/obstacles to progress. Attendance by the public will be limited to space available.

Ms. Rona L. Siskind, Executive Secretary, AIDS Research Advisory Committee, DAIDS, NIAID, NIH, Solar Building, Room 2A21, telephone 301– 435–3732, will provide a summary of the meeting and a roster of committee members upon request. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Siskind in advance of the meeting.

(Catalog of Federal Domestic Assistance Program Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health).

Dated: December 10, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.
[FR Doc. 97–32743 Filed 12–15–97; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

Name of SEP: Amended Unsolicited R01 (Telephone Conference Call).

Date: January 6, 1998.

Time: 1:00 p.m. to Adjournment. Place: Teleconference, 6003 Executive Blvd., Solar Building, Room 4C01, Bethesda, MD 20892, (301) 496–2500.

Contact Person: Dr. Dianne E. Tingley, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C07, Bethesda, MD 20892, (301) 496–2550.

Purpose/Agenda: To evaluate a grant application.

The meeting will be closed in accordance with the provision set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Application and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Programs Nos. 93.855, Immunology, Allergic and Immunologic Diseases Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health.)

Dated: December 10, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.
[FR Doc. 97–32744 Filed 12–15–97; 8:45 am]
BILLING CODE 4140–01–M